In the primary 48-week analysis ( n = 721 ) , maraviroc was noninferior for < 400 copies/mL ( 70.6 % for maraviroc vs 73.1 % for efavirenz ) but not for < 50 copies/mL ( 65.3 % vs 69.3 % ) at a threshold of -10 % .
